Publications
5808 Results
- Journal / Conference
- ASH Annual Meeting (December 6-9, 2025, Orlando, FL). Abstract 3343 poster. Blood (2025) 146 (Supplement 1): 3343
- Year
- 2025
- Research Committee(s)
- Leukemia
- Study Number(s)
- S1318
SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Longer Follow up and Predictors of Outcomes
- Journal / Conference
- Blood Advances 2025 Dec 23;9(24):6443-6454. doi: 10.1182/bloodadvances.2025016827.
- Year
- 2025
- Research Committee(s)
- Lymphoma
- PMID
- 40966421
- PMC
- PMC12755980
- Study Number(s)
- S0016
Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma
- Journal / Conference
- Prostate Cancer Foundation annual meeting (October 23-25, 2025, Carlsbad, CA)
- Year
- 2025
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CCTG-PR26
Clinical Trial of Docetaxel with Androgen Receptor Pathway Inhibitors for Metastatic Castration-Sensitive Prostate Cancer Patients with a Suboptimal PSA Response
- Journal / Conference
- Journal of Clinical Oncology, 2025 Aug 20;43(24):2712-2719. doi: 10.1200/JCO-24-02697. Epub 2025 Jul 9.
- Year
- 2025
- Research Committee(s)
- Cancer Survivorship
- PMID
- 40632989
- Study Number(s)
- CTSU/A221405
Breastfeeding after hormone-receptor positive breast cancer: results from the POSITIVE trial
- Journal / Conference
- JNCI djaf342; publ Dec 4, 2025; 10.1093/jnci/djaf342
- Year
- 2025
- Research Committee(s)
- Cancer Care Delivery
Development and Validation of a Risk Prediction Model for Acute Care Use Among Older Patients with Advanced Cancer on Clinical Trials
- Journal / Conference
- JAMA Network Open. 2026 Apr 1;9(4):e264901. doi: 10.1001/jamanetworkopen.2026.4901.
- Year
- 2025
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- 41961500
- PMC
- PMC13069458
- Study Number(s)
- S1714
Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer: SWOG S1714
- Journal / Conference
- Nature Cancer. 2026 Feb;7(2):272-282. doi: 10.1038/s43018-025-01113-y. Epub 2026 Jan 29.
- Year
- 2025
- Research Committee(s)
- Melanoma
- PMID
- 41611998
- PMC
- PMC12948668
- Study Number(s)
- S1512
Neoadjuvant PD-1 blockade in patients with surgically resectable desmoplastic 3 melanoma (SWOG S1512 cohort A)
- Journal / Conference
- European Urology Feb;85(2):171-176
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID37085425
- PMC
- PMC10662935
- Study Number(s)
- S1216
Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer: results from the SWOG S1216 phase III trial of androgen deprivation therapy with or without orteronel
- Journal / Conference
- Leukemia Jan;38(1):58-66
- Year
- 2024
- Research Committee(s)
- Leukemia
- PMID
- PMID37935977
- Study Number(s)
- S1203
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
- Journal / Conference
- Clinical Cancer Research Jan 17;30(2):444-449
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID37966367
- PMC
- PMC10824507
- Study Number(s)
- S1314